

## **PLANET<sup>®</sup> Dose is selected by the French Public Hospitals for Targeted Radionuclide Therapies**

DOSIsoft SA, leading provider of advanced software solutions for Radiation Oncology and Nuclear Medicine, has been selected, following a public tender, by the French public hospitals (CH and CHU), through their centralized purchasing organization UniHA, for the supply, installation and commissioning services of PLANET<sup>®</sup> Dose Software Suite dedicated to Targeted Radionuclide Therapies (<sup>90</sup>Yttrium microspheres SIRT / <sup>177</sup>Lutetium based treatments) in Nuclear Medicine.

### **UniHA Internal Dosimetry lot awarded to DOSIsoft**

UniHA is the cooperative network undertaking grouped purchasing for the public hospitals in France. It is one of the largest French public sector purchaser. It centralizes purchasing for 67 public Hospitals Centers (CH) and University Hospital Centers (CHU).

Following the open public tender launched in the second semester of 2017, DOSIsoft has been awarded the Internal Dosimetry lot, and becomes the unique supplier of UniHA, in the field of nuclear medicine, of software solutions for 3D personalized treatment planning and *in vivo* dosimetry dedicated to radionuclide-based Targeted Radionuclide Therapies (TRT).

### **PLANET<sup>®</sup> Dose: the fully integrated 3D personalized dosimetry and imaging software for TRT**

PLANET<sup>®</sup> Dose is a complete, versatile, high performance and vendor-neutral solution to assist in the planning and *in vivo* dosimetry of Targeted Radionuclide Therapies (TRT). Benefiting from all the advanced functionalities of PLANET<sup>®</sup> Onco dedicated to molecular imaging, PLANET<sup>®</sup> Dose also provides complete workflow for cancer diagnosis and staging, lesion contouring, advanced quantification as well as therapy response assessment. PLANET<sup>®</sup> Dose is CE marked since March 2016.

PLANET<sup>®</sup> Dose is the first fully integrated 3D imaging and dosimetry platform supporting multiple radionuclides (<sup>90</sup>Yttrium / <sup>177</sup>Lutetium) and available for clinical use. It perfectly meets the new regulatory requirements in Europe regarding dosimetry of ionizing radiations.

*"We are extremely proud to have been selected by UniHA central purchasing group of the French public hospitals, investing into the new and promising Targeted Radionuclide Therapies. This strengthens our leading position on the market and confirms the validity of our R&D investments, bringing advanced External Radiation Therapy technologies to the Nuclear Medicine space, combining imaging, dosimetry, treatment planning and in vivo control into a complete workflow-oriented solution"* highlights Marc Uszynski, CEO of DOSIsoft.

**About UniHA** - Grouped Purchasing Organization, created in 2005, of public hospitals in France. Largest French public-sector purchaser, it regroups purchasing of 67 public hospitals. UniHA is the purchasing community for hospitals professionals, created at their initiative, and for the benefit of hospitals and patients. [www.uniha.org](http://www.uniha.org)

**About DOSIsoft** - Founded in 2002, DOSIsoft develops cutting-edge software solutions for Radiation Oncology and Nuclear Medicine. 15 years of innovation and R&D investments have led to world leading software solutions used successfully in over 160 hospital centers in 18 countries around the world. Spin-off between Gustave Roussy and Institut Curie, DOSIsoft constantly innovates in partnership with the major cancer institutes and research centers in the world. [www.dosisoft.com](http://www.dosisoft.com)